サンプルお申込み

お問い合わせ

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は肺動脈性肺高血圧症(PAH)市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは肺動脈性肺高血圧症(PAH)の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の肺動脈性肺高血圧症(PAH)市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは肺動脈性肺高血圧症(PAH)のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に肺動脈性肺高血圧症(PAH)市場を分類しています。本研究に含まれる主な企業は：Actelion、Gilead Sciences、United Therapeutics、GlaxoSmithKline、Pfizer、Bayer、Arena

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5

用途別の市場セグメント：
    Hospital
    Clinic

本レポートの詳細内容
世界の肺動脈性肺高血圧症(PAH)市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、肺動脈性肺高血圧症(PAH)タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の肺動脈性肺高血圧症(PAH)収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の肺動脈性肺高血圧症(PAH)市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、肺動脈性肺高血圧症(PAH)市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

肺動脈性肺高血圧症(PAH)のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：肺動脈性肺高血圧症(PAH)のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：肺動脈性肺高血圧症(PAH)の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章肺動脈性肺高血圧症(PAH)企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：肺動脈性肺高血圧症(PAH)の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：肺動脈性肺高血圧症(PAH)の主要企業の概要を提供し、製品の説明と仕様、肺動脈性肺高血圧症(PAH)の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market
The global Pulmonary Arterial Hypertension (PAH) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The Europe market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The global key companies of Pulmonary Arterial Hypertension (PAH) include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Pulmonary Arterial Hypertension (PAH) is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Pulmonary Arterial Hypertension (PAH) industry development. In 2023, global % revenue of Pulmonary Arterial Hypertension (PAH) went into Hospital filed and the proportion will reach to % in 2030. 
Report Covers:
This report presents an overview of global market for Pulmonary Arterial Hypertension (PAH) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Pulmonary Arterial Hypertension (PAH), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Pulmonary Arterial Hypertension (PAH), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pulmonary Arterial Hypertension (PAH) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Pulmonary Arterial Hypertension (PAH) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Pulmonary Arterial Hypertension (PAH) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc.

Market Segmentation
By Company
    Actelion
    Gilead Sciences
    United Therapeutics
    GlaxoSmithKline
    Pfizer
    Bayer
    Arena

Segment by Type
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5

Segment by Application
    Hospital
    Clinic

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Pulmonary Arterial Hypertension (PAH) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Arterial Hypertension (PAH) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Prostacyclin and Prostacyclin Analogs
    Table 3. Key Players of SGC Stimulators
    Table 4. Key Players of ERA
    Table 5. Key Players of PDE-5
    Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2019-2024)
    Table 10. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2025-2030)
    Table 12. Pulmonary Arterial Hypertension (PAH) Market Trends
    Table 13. Pulmonary Arterial Hypertension (PAH) Market Drivers
    Table 14. Pulmonary Arterial Hypertension (PAH) Market Challenges
    Table 15. Pulmonary Arterial Hypertension (PAH) Market Restraints
    Table 16. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Players (2019-2024)
    Table 18. Global Top Pulmonary Arterial Hypertension (PAH) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2023)
    Table 19. Global Pulmonary Arterial Hypertension (PAH) Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Pulmonary Arterial Hypertension (PAH), Headquarters and Area Served
    Table 22. Global Key Players of Pulmonary Arterial Hypertension (PAH), Product and Application
    Table 23. Global Key Players of Pulmonary Arterial Hypertension (PAH), Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2019-2024)
    Table 27. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2025-2030)
    Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Application (2019-2024)
    Table 31. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Application (2025-2030)
    Table 33. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Pulmonary Arterial Hypertension (PAH) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Pulmonary Arterial Hypertension (PAH) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Pulmonary Arterial Hypertension (PAH) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Pulmonary Arterial Hypertension (PAH) Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030) & (US$ Million)
    Table 65. Actelion Company Details
    Table 66. Actelion Business Overview
    Table 67. Actelion Pulmonary Arterial Hypertension (PAH) Product
    Table 68. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 69. Actelion Recent Developments
    Table 70. Gilead Sciences Company Details
    Table 71. Gilead Sciences Business Overview
    Table 72. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product
    Table 73. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 74. Gilead Sciences Recent Developments
    Table 75. United Therapeutics Company Details
    Table 76. United Therapeutics Business Overview
    Table 77. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product
    Table 78. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 79. United Therapeutics Recent Developments
    Table 80. GlaxoSmithKline Company Details
    Table 81. GlaxoSmithKline Business Overview
    Table 82. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product
    Table 83. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 84. GlaxoSmithKline Recent Developments
    Table 85. Pfizer Company Details
    Table 86. Pfizer Business Overview
    Table 87. Pfizer Pulmonary Arterial Hypertension (PAH) Product
    Table 88. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 89. Pfizer Recent Developments
    Table 90. Bayer Company Details
    Table 91. Bayer Business Overview
    Table 92. Bayer Pulmonary Arterial Hypertension (PAH) Product
    Table 93. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 94. Bayer Recent Developments
    Table 95. Arena Company Details
    Table 96. Arena Business Overview
    Table 97. Arena Pulmonary Arterial Hypertension (PAH) Product
    Table 98. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024) & (US$ Million)
    Table 99. Arena Recent Developments
    Table 100. Research Programs/Design for This Report
    Table 101. Key Data Information from Secondary Sources
    Table 102. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2023 VS 2030
    Figure 3. Prostacyclin and Prostacyclin Analogs Features
    Figure 4. SGC Stimulators Features
    Figure 5. ERA Features
    Figure 6. PDE-5 Features
    Figure 7. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2023 VS 2030
    Figure 9. Hospital Case Studies
    Figure 10. Clinic Case Studies
    Figure 11. Pulmonary Arterial Hypertension (PAH) Report Years Considered
    Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Pulmonary Arterial Hypertension (PAH) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region: 2023 VS 2030
    Figure 15. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2023
    Figure 16. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2023
    Figure 18. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2019-2030)
    Figure 20. North America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2019-2030)
    Figure 21. North America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2019-2030)
    Figure 22. United States Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Type (2019-2030)
    Figure 26. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Application (2019-2030)
    Figure 27. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Country (2019-2030)
    Figure 28. Germany Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Pulmonary Arterial Hypertension (PAH) Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Pulmonary Arterial Hypertension (PAH) Market Share by Type (2019-2030)
    Figure 36. China Pulmonary Arterial Hypertension (PAH) Market Share by Application (2019-2030)
    Figure 37. Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Pulmonary Arterial Hypertension (PAH) Market Share by Type (2019-2030)
    Figure 39. Asia Pulmonary Arterial Hypertension (PAH) Market Share by Application (2019-2030)
    Figure 40. Asia Pulmonary Arterial Hypertension (PAH) Market Share by Region (2019-2030)
    Figure 41. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2019-2030)
    Figure 51. Brazil Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Actelion Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 58. Gilead Sciences Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 59. United Therapeutics Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 60. GlaxoSmithKline Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 61. Pfizer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 62. Bayer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 63. Arena Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed